

## FREEDOM OF INFORMATION REQUEST

RF24-112

### Request:

1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

- Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
- Abemaciclib + Fulvestrant
- Alpelisib + Fulvestrant
- Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
- Atezolizumab +Nab-paclitaxel/Paclitaxel
- Capecitabine as a single agent
- Eribulin as a single agent or in combination
- Everolimus + Exemestane
- Fulvestrant as a single agent
- Lapatinib
- Neratinib
- Parp Inhibitors (Olaparib/Talazoparib)
- Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
- Palbociclib + Fulvestrant
- Pembrolizumab
- Platinum (e.g. carboplatin or cisplatin) as a single agent
- Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
- Ribociclib + Fulvestrant
- Sacituzumab Govitecan
- Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
- Taxane and/or Anthracycline in combination
- Trastuzumab as a single agent or in combination
- Trastuzumab emtansine
- Transtuzumab deruxtecan
- Any other active systemic anti-cancer therapy

2. Does your trust participate in any clinical trials for breast cancer? If so, please provide the name of each trial, and the number of patients taking part

### Response:

We can confirm East Kent Hospitals University NHS Foundation Trust (EKHUFT) holds the information you have requested.

1.

Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	<b>38</b>
Abemaciclib + Fulvestrant	<b>11</b>
Alpelisib + Fulvestrant	<b>3</b>
Anthracycline (e.g. doxorubicin or epirubicin) as a single agent	<b>1</b>
Atezolizumab +Nab-paclitaxel/Paclitaxel	<b>2</b>
Capecitabine as a single agent	<b>28</b>

Eribulin as a single agent or in combination	<b>3</b>
Everolimus + Exemestane	<b>2</b>
Fulvestrant as a single agent	<b>0</b>
Lapatinib	<b>0</b>
Neratinib	<b>0</b>
Parp Inhibitors (Olaparib/Talazoparib)	<b>1</b>
Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	<b>74</b>
Palbociclib + Fulvestrant	<b>18</b>
Pembrolizumab	<b>1</b>
Platinum (e.g. carboplatin or cisplatin) as a single agent	<b>1</b>
Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	<b>13</b>
Ribociclib + Fulvestrant	<b>1</b>
Sacituzumab Govitecan	<b>1</b>
Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent	<b>4</b>
Taxane and/or Anthracycline in combination	<b>22</b>
Trastuzumab as a single agent or in combination	<b>34</b>
Trastuzumab emtansine	<b>23</b>
Trastuzumab deruxtecan	<b>1</b>
Any other active systemic anti-cancer therapy	<b>232</b>

2.

EKHUFT are currently running the following Breast trials:

OPTIMA:

- IRAS No: 95626
- 46 Patients on trial follow up
- Still open to recruitment

HER2-RADiCAL

- IRAS No: 292122
- 12 participants
- Still open to recruitment

ADD ASPRIN

- 32 patients in follow up

**(DATE OF RESPONSE: 19 FEBRUARY 2024)**